4//SEC Filing
Heerma Peter 4
Accession 0001415889-24-002282
CIK 0001438533other
Filed
Feb 1, 7:00 PM ET
Accepted
Feb 2, 4:05 PM ET
Size
9.9 KB
Accession
0001415889-24-002282
Insider Transaction Report
Form 4
Heerma Peter
CHIEF COMMERCIAL OFFICER
Transactions
- Award
Common Stock
2024-01-31+25,000→ 103,698 total - Sale
Common Stock
2024-02-01$8.53/sh−4,195$35,789→ 99,503 total - Award
Employee stock option (right to buy)
2024-01-31+65,000→ 65,000 totalExercise: $8.93Exp: 2034-01-30→ Common Stock (65,000 underlying)
Footnotes (4)
- [F1]Each restricted stock unit represents a contingent right to receive one share of the Common Stock of the Issuer.
- [F2]Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person.
- [F3]The weighted average sale price for the reported transaction was $8.5313, and the range of prices were between $8.5302 and $8.5321. Upon request by the SEC staff, the Issuer or any securityholder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
- [F4]One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of the date of grant, and the remaining shares vest in 36 equal monthly installments thereafter.
Documents
Issuer
Travere Therapeutics, Inc.
CIK 0001438533
Entity typeother
Related Parties
1- filerCIK 0001789617
Filing Metadata
- Form type
- 4
- Filed
- Feb 1, 7:00 PM ET
- Accepted
- Feb 2, 4:05 PM ET
- Size
- 9.9 KB